(S)-2,2-Dimethyl-4-(4-trifluoromethanesulfonyloxy-benzyl)-oxazolidine-3-carboxylic acid tert-butyl ester | 386207-30-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (S)-2,2-Dimethyl-4-(4-trifluoromethanesulfonyloxy-benzyl)-oxazolidine-3-carboxylic acid tert-butyl ester
• 英文别名: tert-butyl (S)-2,2-dimethyl-4-[4-[[(trifluoromethyl)sulfonyl]oxy]benzyl]-1,3-oxazolidine-3-carboxylate；tert-butyl (4S)-2,2-dimethyl-4-[[4-(trifluoromethylsulfonyloxy)phenyl]methyl]-1,3-oxazolidine-3-carboxylate
• CAS: 386207-30-3
• 化学式: C₁₈H₂₄F₃NO₆S
• 分子量: 439.453
• InChiKey: BWYNIAYZQMHGSL-ZDUSSCGKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  29
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.61
• 拓扑面积：
  90.5
• 氢给体数：
  0
• 氢受体数：
  9

反应信息

• 作为反应物：
  描述：

  (S)-2,2-Dimethyl-4-(4-trifluoromethanesulfonyloxy-benzyl)-oxazolidine-3-carboxylic acid tert-butyl ester 在 lithium chloride 4-二甲氨基吡啶 、 sodium chlorite 、 potassium dihydrogenphosphate 、 9-borabicyclo[3.3.1]nonane dimer 、 四(三苯基膦)钯 、 2-甲基-2-丁烯 、 戴斯-马丁氧化剂 、 N,N'-二环己基碳二亚胺 作用下， 以 四氢呋喃 、 二氯甲烷 、 水 、 叔丁醇 为溶剂， 反应 47.0h， 生成 (S)-4-[4-((1R,2S,3R)-2,3-Bis-benzyloxy-1-benzyloxymethyl-pent-4-enyloxycarbonylmethyl)-benzyl]-2,2-dimethyl-oxazolidine-3-carboxylic acid tert-butyl ester
  参考文献：
  名称：

  RCM-Based Synthesis of a Variety of β-C-Glycosides and Their in Vitro Anti-Solid Tumor Activity

  摘要：

  The synthesis of a number of biologically relevant C-glycosides has been carried out through the use of an esterification-ring-closing metathesis (RCM) strategy. The required acid precursors were readily prepared via a number of standard chemical transformations followed by dehydrative coupling of these acids with several olefin alcohols 1 to yield the precursor esters 3 in excellent yield. Methylenation of the esters 3 was followed by RCM and in situ hydroboration-oxidation of the formed glycals to furnish the protected beta-C-glycosides 6 in good overall yield. Several examples were converted to the corresponding C-glycoglycerolipids 17 and subsequently screened against solid-tumor cell lines for in vitro differential cytotoxicity.

  DOI：

  10.1021/jo040254t
• 作为产物：
  描述：

  三氟甲磺酸酐 、 N-(tert-butoxycarbonyl)-2,2-dimethyl-4-(4-hydroxyphenyl)-1,3-oxazolidine 在 4-二甲氨基吡啶 、 三乙胺 作用下， 以 二氯甲烷 为溶剂， 以86%的产率得到(S)-2,2-Dimethyl-4-(4-trifluoromethanesulfonyloxy-benzyl)-oxazolidine-3-carboxylic acid tert-butyl ester
  参考文献：
  名称：

  RCM-Based Synthesis of a Variety of β-C-Glycosides and Their in Vitro Anti-Solid Tumor Activity

  摘要：

  The synthesis of a number of biologically relevant C-glycosides has been carried out through the use of an esterification-ring-closing metathesis (RCM) strategy. The required acid precursors were readily prepared via a number of standard chemical transformations followed by dehydrative coupling of these acids with several olefin alcohols 1 to yield the precursor esters 3 in excellent yield. Methylenation of the esters 3 was followed by RCM and in situ hydroboration-oxidation of the formed glycals to furnish the protected beta-C-glycosides 6 in good overall yield. Several examples were converted to the corresponding C-glycoglycerolipids 17 and subsequently screened against solid-tumor cell lines for in vitro differential cytotoxicity.

  DOI：

  10.1021/jo040254t

文献信息

• Aminoalcohol derivatives
  申请人：——

  公开号：US20040138462A1

  公开（公告）日：2004-07-15

  The present invention relates to a compound formula wherein R 1 is phenyl, pyridyl, etc., each of which may be substituted with one or two substituent(s); R 2 is hydrogen, an amino protective group, etc.; R 3 and R 4 are each independently hydrogen, lower alkyl or hydroxy(lower)alkyl; R 5 is aryl, ar(lower)alkyl, etc., each of which may be substituted with one, two or three substituent(s); R 8 is hydrogen or halogen, X is a single bond or O—CH 2 —, and n is 0, 1 or 2, or a salt thereof. The compound [I] of the present invention and pharmaceutically acceptable salts thereof are useful for the prophylactic and/or the therapeutic treatment of pollakiurea or urinary incontinence. 1

  本发明涉及一种化合物配方，其中R1是苯基，吡啶基等，每个基团可以用一个或两个取代基取代；R2是氢，氨基保护基等；R3和R4各自独立地是氢，低碳基或羟基（低）碳基；R5是芳基，芳（低）碳基等，每个基团可以用一个、两个或三个取代基取代；R8是氢或卤素，X是单键或O-CH2-，n为0、1或2，或其盐。本发明的化合物[I]及其药学上可接受的盐对预防和/或治疗多尿或尿失禁非常有用。
• [EN] NEW AMINOALCOHOL DERIVATIVES<br/>[FR] NOUVEAUX DERIVES D'AMINOALCOOL
  申请人：FUJISAWA PHARMACEUTICAL CO

  公开号：WO2002000622A2

  公开（公告）日：2002-01-03

  The present invention relates to a compound of formula (I): wherein X1 is bond or -OCH2-; X2 is -(CH2)n-, in which n is 1 or 2; X3 is bond, -O- or -NH-; R1 is phenyl, indolyl or carbazolyl, each of which is optionally substituted with one or two substituent(s) selected from the group consisting of hydroxy, halogen, nitro, amino, formyl, (lower)alkylsulfonylamino, aryl(lower)alkoxy and hydroxy(lower)alkyl; R2 is hydrogen or aryl(lower)alkyl; R3 is hydrogen or hydroxy(lower)alkyl; R4 is aryl, 4-quinolyl, phthalazinyl, quinazolinyl, cinnolinyl or naphthyridinyl, each of which is optionally substituted with one or two substituent(s) defined in the specification, or a salt thereof. The compound (I) of the present invention and pharmaceutically acceptable salts thereof are useful for the prophylactic and/or the therapeutic treatment of pollakiurea or urinary incontinence.
• RCM-Based Synthesis of a Variety of β-<i>C</i>-Glycosides and Their in Vitro Anti-Solid Tumor Activity
  作者：Maarten H. D. Postema、Jared L. Piper、Russell L. Betts、Frederick A. Valeriote、Halina Pietraszkewicz

  DOI：10.1021/jo040254t

  日期：2005.2.1

  The synthesis of a number of biologically relevant C-glycosides has been carried out through the use of an esterification-ring-closing metathesis (RCM) strategy. The required acid precursors were readily prepared via a number of standard chemical transformations followed by dehydrative coupling of these acids with several olefin alcohols 1 to yield the precursor esters 3 in excellent yield. Methylenation of the esters 3 was followed by RCM and in situ hydroboration-oxidation of the formed glycals to furnish the protected beta-C-glycosides 6 in good overall yield. Several examples were converted to the corresponding C-glycoglycerolipids 17 and subsequently screened against solid-tumor cell lines for in vitro differential cytotoxicity.